Revive Therapeutics

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business of Psychedelics, BitcoinMay 2, 2025
Psychedelics Namechecked in Trump Cabinet Meeting • Noma Therapy Raises $4.25M, Aims to Disrupt At-Home Ketamine With Insurance-Friendly Approach • Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet • and more...
March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s SpinoutMay 1, 2025
Explore or interactive database of psychedelic patent activity in March and April 2025 via our new interface. We also cover a handful of related headlines: from Lykos Therapeutics’ latest MDMA-related patent woes to a patent application-assisted peek under the hood of Seaport Therapeutics’ 2-Bromo-LSD program.
Dispatch from Breaking Convention 2025: Insights from Europe’s Largest Psychedelic Research Conference (Part 1)April 29, 2025
The UK’s seventh biennial international conference on psychedelic consciousness welcomed researchers, clinicians and delegates to the University of Exeter from 17–19 April. In this first instalment, we dive into ketamine’s path into public healthcare, efficient and ethical trial designs, overlooked risks in the underground psychedelic scene, and whether new modalities of care can avoid repeating psychiatry’s historic mistakes.
Pα+ Psychedelic Bulletin #194: Make-or-Break Moment Looms for Compass; RFK Jr. Discusses LSD Use; Europe’s Next Chapter in Psychedelic Therapy Begins in BarcelonaApril 25, 2025
Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona • Make-or-Break Moment Looms for Compass Pathways • Makary Outlines Vision for Faster Drug Approvals • RFK Jr. Details Teenage Acid Trip That Preceded Years of Addiction • Enthea Ventures into Oregon’s Psilocybin Services • A Neuroimmune Theory of Psychedelic Action? • Pilot Study Explores Psilocybin for Mood Dysfunction in Parkinson’s Disease • and more...
Psychedelic Funding Update: Q1 2025April 22, 2025
Q1 2025 saw roughly $350M flow into the psychedelics industry, the majority of which accrued to a trio of publicly-trader drug developers. Explore key trends, private vs. public dynamics, and what Compass Pathways’ upcoming Phase 3 results could mean for the remainder of 2025.

Revive Therapeutics

Latest News

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights